Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.

Cho H, Kang H, Lee HH, Kim CW.

Int J Mol Sci. 2017 Jul 13;18(7). pii: E1517. doi: 10.3390/ijms18071517. Review.

2.

B7-H3 role in the immune landscape of cancer.

Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, Asuthkar S.

Am J Clin Exp Immunol. 2017 Jun 15;6(4):66-75. eCollection 2017. Review.

3.

Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition.

Peer S, Baier G, Gruber T.

Oncotarget. 2017 Jun 27;8(26):41841-41853. doi: 10.18632/oncotarget.18360.

4.

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.

Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S.

Front Oncol. 2017 Apr 18;7:64. doi: 10.3389/fonc.2017.00064. eCollection 2017. Review.

5.

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Patsoukis N, Weaver JD, Strauss L, Herbel C, Seth P, Boussiotis VA.

Front Immunol. 2017 Apr 11;8:330. doi: 10.3389/fimmu.2017.00330. eCollection 2017. Review.

6.

Tuning cancer fate: the unremitting role of host immunity.

Calì B, Molon B, Viola A.

Open Biol. 2017 Apr;7(4). pii: 170006. doi: 10.1098/rsob.170006. Review.

7.

Immunotherapy in pancreatic cancer treatment: a new frontier.

Thind K, Padrnos LJ, Ramanathan RK, Borad MJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):168-194. doi: 10.1177/1756283X16667909. Epub 2016 Oct 17. Review.

8.

A New VISTA on combination therapy for negative checkpoint regulator blockade.

Deng J, Le Mercier I, Kuta A, Noelle RJ.

J Immunother Cancer. 2016 Dec 20;4:86. doi: 10.1186/s40425-016-0190-5. eCollection 2016. Review.

9.

Update on immune checkpoint inhibitors in gynecological cancers.

Heong V, Ngoi N, Tan DS.

J Gynecol Oncol. 2017 Mar;28(2):e20. doi: 10.3802/jgo.2017.28.e20. Epub 2016 Dec 14. Review.

10.

Molecular Pathways: The Necrosome-A Target for Cancer Therapy.

Seifert L, Miller G.

Clin Cancer Res. 2017 Mar 1;23(5):1132-1136. doi: 10.1158/1078-0432.CCR-16-0968. Epub 2016 Dec 8.

PMID:
27932417
11.

Live Imaging of Immune Responses in Experimental Models of Multiple Sclerosis.

Rossi B, Constantin G.

Front Immunol. 2016 Nov 21;7:506. eCollection 2016. Review.

12.

Artery Tertiary Lymphoid Organs: Powerhouses of Atherosclerosis Immunity.

Yin C, Mohanta SK, Srikakulapu P, Weber C, Habenicht AJ.

Front Immunol. 2016 Oct 10;7:387. eCollection 2016. Review.

13.
14.

Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.

Mitsis D, Francescutti V, Skitzki J.

Sarcoma. 2016;2016:9757219. Epub 2016 Sep 14. Review.

15.

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Moreno-Cubero E, Larrubia JR.

World J Gastroenterol. 2016 Jul 28;22(28):6469-83. doi: 10.3748/wjg.v22.i28.6469. Review.

16.

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Vardhana S, Younes A.

Haematologica. 2016 Jul;101(7):794-802. doi: 10.3324/haematol.2015.132761. Review.

17.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

18.

Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) Gene Polymorphisms with Autoimmune Thyroid Disease in Children and Adults: Case-Control Study.

Ting WH, Chien MN, Lo FS, Wang CH, Huang CY, Lin CL, Lin WS, Chang TY, Yang HW, Chen WF, Lien YP, Cheng BW, Lin CH, Chen CC, Wu YL, Hung CM, Li HJ, Chan CI, Lee YJ.

PLoS One. 2016 Apr 25;11(4):e0154394. doi: 10.1371/journal.pone.0154394. eCollection 2016.

19.

Abatacept Treatment Does Not Preserve Renal Function in the Streptozocin-Induced Model of Diabetic Nephropathy.

Norlin J, Nielsen Fink L, Helding Kvist P, Douglas Galsgaard E, Coppieters K.

PLoS One. 2016 Apr 7;11(4):e0152315. doi: 10.1371/journal.pone.0152315. eCollection 2016.

20.

Non-cleavable talin rescues defect in the T-cell conjugation of T-cells deficient in the immune adaptor SKAP1.

Lim D, Lu Y, Rudd CE.

Immunol Lett. 2016 Apr;172:40-6. doi: 10.1016/j.imlet.2016.02.004. Epub 2016 Feb 19.

Supplemental Content

Support Center